Figure 4From: Joint distribution approaches to simultaneously quantifying benefit and risk PR [ INHB BR ( δ ) > 0] over a range of 1/ δ values for the PROPHET study. Posterior probabilities that the incremental net health benefit (INHB BR ) of hydrocortisone compared to placebo exceeds zero as a function of the minimum number of babies who should survive without supplemental oxygen for each additional GI perforation.Back to article page